Screener
Halozyme Therapeutics HALO Net debt
Discontinued — last reported Q2 '26
Net debt at other companies
Other financials
Where this comes from
Calculated from Halozyme Therapeutics’s reported figures.
The source filing: Halozyme Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001159036-26-000104
FAQ
- What is Halozyme Therapeutics's net debt?
- Halozyme Therapeutics (HALO) reported net debt of $2.01B in Q2 2026.
- How has Halozyme Therapeutics's net debt changed year-over-year?
- Halozyme Therapeutics's net debt increased by 36.5% year-over-year, from $1.48B to $2.01B.
- What is the long-term trend for Halozyme Therapeutics's net debt?
- Over 5 years (2020 to 2025), Halozyme Therapeutics's net debt has grown at a 51.7% compound annual growth rate (CAGR), from $253.89M to $2.04B.
- What does net debt mean?
- Total debt minus cash and equivalents at the quarter end. The debt that would remain if the company used all its cash to pay down borrowings.
Ask your AI about Halozyme Therapeutics's net debt.
Connect your AI assistant and see it in context, right in your chat.
Connect your AI
Claude